secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001493152-23-029169
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Q2 revenue falls to $3.4M (-19% YoY); net loss narrows 21% but now expects added financing
--------------------------------------------------------------------------------

- Revenue $3.4M, down 19% YoY from $4.2M; gross profit $2.1M (62% margin).
- Net loss reduced by $1.5M (21% YoY) reflecting cost cuts.
- Operating expenses cut 31% YoY ($2.9M reduction).
- Cash $3.9M; now expects to need additional financing as sales growth stalled.
- Patients treated ~40,000 (up from ~28,000); DSO pilots and first DME distribution deal signed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/0001493152-23-029169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223029169/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-029169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer